vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-840Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEЦИСТАТИН С КАК МАРКЕР НЕФРОТОКСИЧНОСТИ ЦИКЛОСПОРИНА А У ДЕТЕЙ С НЕФРОТИЧЕСКИМ СИНДРОМОМCYSTATIN S AS A MARKER OF CYCLOSPORINE A RENAL TOXICITY IN CHILDREN WITH NEPHROTIC SYNDROMEКомароваО.В.KomarovaO.V.РожковаМ.В.RozhkovaM.V.ЦыгинА.Н.TsyginA.N.КучеренкоА.Г.KucherenkoA.G.СмирновИ.Е.SmirnovI.E.ЛеоноваЛ.В.LeonovaL.V.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссия20101409201591Вопросы современной педиатрии131135Copyright © Комарова О., Рожкова М., Цыгин А., Кучеренко А., Смирнов И., Леонова Л., 20102010Комарова О., Рожкова М., Цыгин А., Кучеренко А., Смирнов И., Леонова Л.Komarova O., Rozhkova M., Tsygin A., Kucherenko A., Smirnov I., Leonova L.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/840

Большой интерес представляет использование цистатина С (ЦсС) в качестве возможного маркера нефротоксического действия циклоспорина А (ЦсА) у детей с нефротическим синдромом, длительно лечившихся этим препаратом. В настоящем исследовании у детей (n = 29), получающих циклоспорин А и разделенных на 3 группы в зависимости от длительности терапии (менее 1 года, 1–2 года, более 2 лет) отмечено повышение уровня ЦсС по сравнению с таковым в контрольной группе (10 детей без патологии почек). Наиболее высоким его уровень был у детей, получавших ЦсА в терапевтических дозах (от 3 до 5 мг/кг в сут) более года. Обнаружена положительная корреляция уровня ЦсС в сыворотке крови с дозой препарата.

Ключевые слова: дети, нефротический синдром, цистатин С, циклоспорин А.(Вопросы современной педиатрии. 2010;9(1):131-135)

The use of cystatin С as a probable marker of renal toxicity of cyclosporine A in children with nephritic syndrome, treated with this medication for a long time, is the subject of an interest. The present study included 29 children treated with cyclosporine A, divided into 3 groups depending on the duration of treatment (< 1 year, 1–2 years and > 2 years). The increase of cystatin С level in these groups compared with cystatin С level in control group (10 children without diseases of kidney) was marked. The highest level of cystatin С was detected in children treated with therapeutic doses of cyclosporine A (3–5 mg/kg daily) over 1 year. Authors showed positive correlation between cystatin С level in serum and medication’s dose.

Key words: children, nephritic syndrome, cystatin С, cyclosporine A.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):131-135)

ReferencesЦыгин А.Н., Комарова О.В., Сергеева Т.В. и др. Нефротический синдром. Клинические рекомендации по педиатрии. Под ред. А.А. Баранова М.: ГЕОТАР–Медиа. 2009. C. 239–261.Цыгин А.Н., Комарова О.В., Сергеева Т.В. и др. Нефротический синдром. Клинические рекомендации по педиатрии. Под ред. А.А. Баранова М.: ГЕОТАР–Медиа. 2009. C. 239–261.Ponticelli C., Edefonti A., Ghio L. et al. Cyclosporine versus cyclophosphamide for patients with steroid dependent and frequently relapsing nephritic syndrome: a multicenter randomized controlled trial. Nephrol. Dial. Transplant. 1993; 8: 1326–1332.Ponticelli C., Edefonti A., Ghio L. et al. Cyclosporine versus cyclophosphamide for patients with steroid dependent and frequently relapsing nephritic syndrome: a multicenter randomized controlled trial. Nephrol. Dial. Transplant. 1993; 8: 1326–1332.Takeda A., Takimoto H., Mizusawa Y. еt al. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 2001; 16: 888–893.Takeda A., Takimoto H., Mizusawa Y. еt al. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 2001; 16: 888–893.Niaudet P. Long term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 2009; 4: 1547–1548.Niaudet P. Long term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 2009; 4: 1547–1548.Cattran D.C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kid. Int. 2007; 72: 1429–1447.Cattran D.C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kid. Int. 2007; 72: 1429–1447.Комарова О.В., Цыгин А.Н., Леонова Л.В. и др. Терапия циклоспорином А детей с фокально-сегментарным гломерулосклерозом. Вопросы современной педиатрии. 2009; 8 (5): 93–97.Комарова О.В., Цыгин А.Н., Леонова Л.В. и др. Терапия циклоспорином А детей с фокально-сегментарным гломерулосклерозом. Вопросы современной педиатрии. 2009; 8 (5): 93–97.Meyrier A., Noel L.H., Auriche P. et al. Long term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. 1994; 45 (5): 1446–1456.Meyrier A., Noel L.H., Auriche P. et al. Long term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. 1994; 45 (5): 1446–1456.El–Husseini A., El–Basuony F., Mahmoud I. et al. Long term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single center experience. Nephrol. Dial. Transplant. 2005; 20 (11): 2433–2438.El–Husseini A., El–Basuony F., Mahmoud I. et al. Long term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single center experience. Nephrol. Dial. Transplant. 2005; 20 (11): 2433–2438.Schiff J., Cole E., Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephorl. 2007; 2: 374–384.Schiff J., Cole E., Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephorl. 2007; 2: 374–384.Seikaly M.G., Prashner H., Nolde–Hurlbert B., Browne R. Long term clinical and pathological effects of cyclosporine in children with nephrosis. Pediatr. Nephrol. 2000; 14: 214–217.Seikaly M.G., Prashner H., Nolde–Hurlbert B., Browne R. Long term clinical and pathological effects of cyclosporine in children with nephrosis. Pediatr. Nephrol. 2000; 14: 214–217.Kengne S.W., Massella L., Diomedi F.C. et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid dependent nephrotic syndrome.Kengne S.W., Massella L., Diomedi F.C. et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid dependent nephrotic syndrome.Clin. J. Am. Soc. Nephrol. 2009; 4 (9): 1409–1416.Clin. J. Am. Soc. Nephrol. 2009; 4 (9): 1409–1416.National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am. J Kidney Dis. 2005; 1: 1–226.National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am. J Kidney Dis. 2005; 1: 1–226.Cockcroft D., Gault V. Prediction of creatinine clearance form serum creatinine. Nephron. 1976; 16: 31–41.Cockcroft D., Gault V. Prediction of creatinine clearance form serum creatinine. Nephron. 1976; 16: 31–41.Pierrat A., Gravier E., Saundrs C. et al. Predicting GRF in children and adults: a comparison of the Cockcroft–Gault, Schwartz and Modification of diet in renal disease formulas. Kidney Int. 2003; 63: 1425–1436.Pierrat A., Gravier E., Saundrs C. et al. Predicting GRF in children and adults: a comparison of the Cockcroft–Gault, Schwartz and Modification of diet in renal disease formulas. Kidney Int. 2003; 63: 1425–1436.Schwartz G., Haycock G., Edelmann C. et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976; 58: 259–263.Schwartz G., Haycock G., Edelmann C. et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976; 58: 259–263.Schwartz G.J., Furth S., Cole S.R. et al. Glomerular filtration rate via plazma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int. 2006; 69: 2070–2077.Schwartz G.J., Furth S., Cole S.R. et al. Glomerular filtration rate via plazma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int. 2006; 69: 2070–2077.Mattman A., Eintracht S., Moch T. et al. Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J. Am. Soc. Nephrol. 2006; 17 (2): 487–496.Mattman A., Eintracht S., Moch T. et al. Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J. Am. Soc. Nephrol. 2006; 17 (2): 487–496.Kyhse-Anderson J., Schmidt C., Nordin G. et al. Serum cystatin C, determined by a rapid, automated particle enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 1994; 40: 1921–1926.Kyhse-Anderson J., Schmidt C., Nordin G. et al. Serum cystatin C, determined by a rapid, automated particle enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 1994; 40: 1921–1926.Wu I., Parikh C.R. Screening for kidney diseases: older measures versus novel biomarkers. Clin. J. Am. Soc. Nephrol. 2008; 3: 1895–1901.Wu I., Parikh C.R. Screening for kidney diseases: older measures versus novel biomarkers. Clin. J. Am. Soc. Nephrol. 2008; 3: 1895–1901.Bökenkamp A., Domanetzki M., Zinck R. et al. Reference values for cystatin C serum concentrations in children. Pediatr. Nephrol. 1998; 12: 125–129.Bökenkamp A., Domanetzki M., Zinck R. et al. Reference values for cystatin C serum concentrations in children. Pediatr. Nephrol. 1998; 12: 125–129.Coll E., Botey A., Alvarez L. et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 2000; 36: 29–34.Coll E., Botey A., Alvarez L. et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 2000; 36: 29–34.Резниченко Н.Е., Панфилова Е.Ю., Данкавцева Е.Н. и др. Возможности использования цистатина в кардиологии. Медицинский алфавит. Больница. 2009; 3: 23–26.Резниченко Н.Е., Панфилова Е.Ю., Данкавцева Е.Н. и др. Возможности использования цистатина в кардиологии. Медицинский алфавит. Больница. 2009; 3: 23–26.Premaratne E., Maclsaac R., Finch S. et al. Serial measurements of cystatin C are more accurate than creatinine based methods in detecting declining renal function in type 1 diabetes. Diabetes Care. 2008; 31 (5): 971–973.Premaratne E., Maclsaac R., Finch S. et al. Serial measurements of cystatin C are more accurate than creatinine based methods in detecting declining renal function in type 1 diabetes. Diabetes Care. 2008; 31 (5): 971–973.Hoek F., Kemperman F., Krediet R. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplant. 2003; 18: 2024–2031.Hoek F., Kemperman F., Krediet R. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplant. 2003; 18: 2024–2031.Stevens L., Coresh J., Schmid C. et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 2008; 51 (3): 395–406.Stevens L., Coresh J., Schmid C. et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 2008; 51 (3): 395–406.Zahran A., Qureshi M., Shoker A. Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol. Dial. Transplant. 2007; 22: 2659–2668.Zahran A., Qureshi M., Shoker A. Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol. Dial. Transplant. 2007; 22: 2659–2668.Tanaka A., Aiba T., Otsuka T. et al. Population pharmacokinetic analysis of vancomycin using serum cystatin–C as a marker of renal function. Antimicrob. Agents Chemother. 2009. URL: http://aac.asm.org/cgi/content/abstract/54/2/778Tanaka A., Aiba T., Otsuka T. et al. Population pharmacokinetic analysis of vancomycin using serum cystatin–C as a marker of renal function. Antimicrob. Agents Chemother. 2009. URL: http://aac.asm.org/cgi/content/abstract/54/2/778Filler G., Priem F., Vollmer I. et al. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Ped. Nephrol. 1999; 13: 501–505.Filler G., Priem F., Vollmer I. et al. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Ped. Nephrol. 1999; 13: 501–505.Короленко Т.А., Черканова М.С., Филатова Т.Г. и др. Возрастные изменения содержания цистатина С и С–реактивного белка у здоровых лиц. Terra medica nova. 2007; 1: 13.Короленко Т.А., Черканова М.С., Филатова Т.Г. и др. Возрастные изменения содержания цистатина С и С–реактивного белка у здоровых лиц. Terra medica nova. 2007; 1: 13.

The authors declare that there are no conflicts of interest present.